Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Company Description (as filed with the SEC)
We are an endocrine-focused biopharmaceutical company initially developing our novel long-acting recombinant human growth hormone, VRS-317, for growth hormone deficiency, or GHD, an orphan disease. A key limitation to current recombinant human growth hormone, or rhGH, products is that they impose the burden of daily injections over multiple years, often resulting in poor compliance, which in turn can lead to suboptimal treatment outcomes in GHD patients. Despite this limitation, global annual sales from currently marketed rhGH products have grown to more than $3 billion in 2013. Based on market research, we believe that the market for daily rhGH products can continue to grow up to $4 billion by 2018. VRS-317 is intended to reduce the burden of daily treatment by requiring significantly fewer dosing events and injections, potentially improving compliance and, therefore, treatment outcomes. Accordingly, we believe VRS-317 may take significant market share. ... More ...
Where does VSAR fit in the risk graph?
|Annual EPS Est:||$|
|Quarterly EPS Est:|